[Updated: 12:45 pm Eastern] Bad news out of Genzyme this morning. The Cambridge, MA-based biotech company (NASDAQ: [[ticker:GENZ]]), the world’s largest maker of treatments for rare genetic diseases, said today it is shutting down production at one of its major drug manufacturing plants in Allston, MA after it found a virus that impairs cell growth. … Continue reading “Genzyme Halts Production at Allston Drug Plant After Virus Appears”
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
Seattle’s Pacific Health Summit, the “Davos” of Global Health, Zeroes in on Tuberculosis
Movers and shakers in global health—including a lot of people not named Bill & Melinda—will be buzzing around the Seattle waterfront this week for what some people like to call the “Davos” of global health. Like the World Economic Forum in Davos, Switzerland—another picturesque setting with mountains and water nearby—the Pacific Health Summit is an … Continue reading “Seattle’s Pacific Health Summit, the “Davos” of Global Health, Zeroes in on Tuberculosis”
Glaxo Ends Synta Partnership
GlaxoSmithKline has pulled out of a collaboration with Lexington, MA-based Synta Pharmaceuticals (NASDAQ: [[ticker:SNTA]) to co-develop elesclomol as a cancer treatment. The drug failed earlier this year in a pivotal clinical trial among patients with melanoma that had spread through the body. Synta is now focusing its resources on other drugs in its portfolio, including … Continue reading “Glaxo Ends Synta Partnership”
Trius Looks to Cut a Deal, Gears Up For Final Stage of Trials with New Antibiotic
San Diego-based Trius Therapeutics saw what it wanted from a clinical trial of its new antibiotic against deadly MRSA infections, and now it’s gearing up this summer to take its game to a higher level. Trius reported earlier this week some impressive results from a trial of 188 patients with complicated skin infections who took … Continue reading “Trius Looks to Cut a Deal, Gears Up For Final Stage of Trials with New Antibiotic”
IDRI Offers Flu Vaccine Boosters
The Infectious Disease Research Institute, a Seattle-based nonprofit research center, said today it it is offering a critical ingredient to manufacturers that could increase the world supplies of flu vaccine. IDRI has developed adjuvants, or immune-boosting compounds, that make it possible to give smaller doses that can still protect people against infection. The announcement came … Continue reading “IDRI Offers Flu Vaccine Boosters”
Ardea Sees Early Signs of Effectiveness With Gout Drug
Ardea Biosciences, the San Diego-based developer of a treatment for gout, has shown in a small clinical trial that a treatment its scientists stumbled upon by accident just might work. Ardea (NASDAQ: [[ticker:RDEA]]) said today that 6 of the first 7 patients who got its lead drug candidate for gout were able to bring their … Continue reading “Ardea Sees Early Signs of Effectiveness With Gout Drug”
UW Spinout, Beat BioTherapeutics, Aims to Make Stem Cells for Damaged Hearts
Stem cell researchers have a lot of big dreams, and one is to someday regenerate damaged hearts. That is still many years away from becoming a commercial reality, if ever, but a few University of Washington scientists have formed a new company that hopes to make cells that can replace pacemakers, and someday rebuild damaged … Continue reading “UW Spinout, Beat BioTherapeutics, Aims to Make Stem Cells for Damaged Hearts”
Dendreon Resists Urge to Sell Out, NanoString Nabs $30M, VC Firm Cashes Out on OncoGenex, & More Seattle-Area Life Sciences News
This is definitely not in sync with the economic theme of 2009, but surprisingly, there was a lot of good news in Seattle biotech the past week. —Dendreon CEO Mitchell Gold fielded a lot of questions at the company’s annual shareholder meeting yesterday, and the biggest one of all is whether he’s looking to sell … Continue reading “Dendreon Resists Urge to Sell Out, NanoString Nabs $30M, VC Firm Cashes Out on OncoGenex, & More Seattle-Area Life Sciences News”
Cell Therapeutics, After Raising More Cash, Hands Some Out in Management Bonuses
Cell Therapeutics (NASDAQ: [[ticker:CTIC]]) has been running dangerously low on cash this year, on a “tight-wire act” in the words of CEO James Bianco. Now the board has decided to hand out some rewards to management for not falling off. The compensation committee of the Seattle biotech company’s board agreed on June 4 to pay … Continue reading “Cell Therapeutics, After Raising More Cash, Hands Some Out in Management Bonuses”
Dendreon, Resisting Urge to Sell, Eyes Opportunity to Be Seattle’s Next Immunex
Dendreon CEO Mitch Gold envisions his company becoming the next anchor tenant for the biotechnology industry in Seattle—the first big success story since Immunex in the late 1990s and early 2000s. For those in need of a refresher, Dendreon (NASDAQ: [[ticker:DNDN]]) has been riding a wave of enthusiasm the past couple months, since a clinical … Continue reading “Dendreon, Resisting Urge to Sell, Eyes Opportunity to Be Seattle’s Next Immunex”
MDRNA Raises $10.5M
MDRNA, the Bothell, WA-based developer of RNA interference drug technology, said today it has raised $10.5 million in a stock sale to existing investors. The company (NASDAQ: [[ticker:MRNA]]) agreed to sell 5.25 million shares at $2 apiece, plus warrants to buy the same number of shares at $2.38 over the next 5.5 years. Canaccord Adams … Continue reading “MDRNA Raises $10.5M”
Ventures West Cashes Out Stake in OncoGenex, Developer of Prostate Cancer Drug
Who says you can’t make money investing in biotech? Vancouver, BC-based Ventures West, one of the largest venture firms in Canada, has cashed out on its booming investment in Bothell, WA-based OncoGenex Pharmaceuticals (NASDAQ: [[ticker:OGXI]]). Ventures West disclosed earlier this week in a regulatory filing that it has sold all of its shares in OncoGenex—which … Continue reading “Ventures West Cashes Out Stake in OncoGenex, Developer of Prostate Cancer Drug”
MDRNA Nasal Spray Gets FDA Nod
Bothell, WA-based MDRNA (NASDAQ: [[ticker:MRNA]]) said today that a generic calcitonin nasal spray for osteoporosis has received FDA approval, and has been introduced to the market. The Bothell, WA-based company sold the product in March to Woodcliff Lake, NJ-based Par Pharmaceutical (NYSE: [[ticker:PRX]]), although MDRNA still stands to receive an undisclosed profit share from the … Continue reading “MDRNA Nasal Spray Gets FDA Nod”
NanoString Nabs $30M in Third Venture Round (Which It Hopes Will Be The Last)
NanoString Technologies, a Seattle-based maker of genetic analysis tools, has nailed down $30 million in a third-round venture financing to boost sales of its first product, just as it was running low on cash while it tries to prove itself in the marketplace. The round was led by Clarus Ventures, and was joined by NanoString’s … Continue reading “NanoString Nabs $30M in Third Venture Round (Which It Hopes Will Be The Last)”
Pulmatrix, With One Drug for Multiple Bugs, Aims to Fundamentally Change Flu Treatment
Back in September, I wrote in this space that if a global flu pandemic ever strikes, public health officials might turn to a Lexington, MA-based startup company called Pulmatrix. The pandemic (a bit overblown, I must say) did strike. And yes, the public health officials have been calling Pulmatrix. This company’s technology is nowhere near … Continue reading “Pulmatrix, With One Drug for Multiple Bugs, Aims to Fundamentally Change Flu Treatment”
Trius, Developer of Antibiotic for Deadly MRSA Bacteria, Passes Key Test
Trius Therapeutics, the San Diego-based biotech company, has passed an important milestone in its quest to develop a more convenient, more effective antibiotic against deadly MRSA bacterial infections that people tend to get in the hospital. Trius released results today from a study in which 188 patients with severe skin infections were randomly assigned to … Continue reading “Trius, Developer of Antibiotic for Deadly MRSA Bacteria, Passes Key Test”
Alder Expands Partnership with Schering-Plough, Adds “Significant” Upfront Cash
Alder Biopharmaceuticals, the Bothell, WA-based developer of antibody drugs, is announcing today it has broadened its four-year-old partnership with Kenilworth, NJ-based drug giant Schering-Plough. The new deal calls for Alder to develop new targeted therapies against an undisclosed target on cells associated with a common neurological disease. Financial terms of the deal aren’t being disclosed, … Continue reading “Alder Expands Partnership with Schering-Plough, Adds “Significant” Upfront Cash”
Aileron Snags $40M From Quartet of Pharma Giants to Develop New Class of Drugs
The biotech world will be buzzing today about something called “stapled peptides.” That’s because Cambridge, MA-based Aileron Therapeutics, a pioneering developer of this new class of drugs, has secured $40 million in venture capital from an ensemble cast of investors that includes four of the world’s biggest drugmakers. Aileron’s latest investment round was led by … Continue reading “Aileron Snags $40M From Quartet of Pharma Giants to Develop New Class of Drugs”
Amylin’s Would-Be Savior, Once-Weekly Diabetes Shot, Shows Two-Year Benefit
The dust has settled in the boardroom battle for control over Amylin Pharmaceuticals, and now it’s time to get back to fundamentals. The San Diego-based biotech company hopes to grab the attention of physicians and investors this weekend with some new clinical trial data that suggests its once-weekly shot for diabetes was able to maintain … Continue reading “Amylin’s Would-Be Savior, Once-Weekly Diabetes Shot, Shows Two-Year Benefit”
Calistoga Drug Shrinks Tumors as Study Grows
Calistoga Pharmaceuticals, the Seattle-based biotech company, said today that its lead drug in development was able to at least partially shrink tumors in 12 of the first 24 patients with blood cancers in a clinical trial. The data were presented today at the European Hematology Association meeting in Berlin, Germany. This finding buttresses some more … Continue reading “Calistoga Drug Shrinks Tumors as Study Grows”
Arena Obesity Drug Helps Patients Shed a Few Pounds, Lower Risk of Heart Disease
San Diego-based Arena Pharmaceuticals disappointed a lot of investors a couple months ago when its obesity drug didn’t help people shed as many pounds as hoped. But after combing through the data in greater detail, the company says it has evidence that its drug can help many patients lose weight, and that it leads to … Continue reading “Arena Obesity Drug Helps Patients Shed a Few Pounds, Lower Risk of Heart Disease”
Orexigen Obesity Drug Produces “Modest” Weight Loss, Lowers Cardiovascular Risk
Orexigen Therapeutics, the San Diego-based obesity drug developer, underwhelmed investors back in January with its incremental ability to help patients lose weight. But now the company is presenting more detailed results from a clinical trial that says it had a positive effect on lowering the risk of heart disease while improving patients’ quality of life. … Continue reading “Orexigen Obesity Drug Produces “Modest” Weight Loss, Lowers Cardiovascular Risk”
Optimer Rides Investment See-Saw With Promising Drug for “C.diff” Infections
Biotech investing can sometimes be a downright confusing game, even for people who are supposed to know what they are talking about. Ask the folks at San Diego-based Optimer Pharmaceuticals (NASDAQ: [[ticker:OPTR]]). Optimer has been one of a few bright spots in biotech over the past year. Back in November, its lead drug candidate, an … Continue reading “Optimer Rides Investment See-Saw With Promising Drug for “C.diff” Infections”
AVI Gets $3M For Muscular Dystrophy
AVI Biopharma (NASDAQ:[[ticker:AVII]]), the Portland, OR-based developer of RNA-based therapies, said today it will receive another $3 million from Charley’s Fund to further develop an experimental drug for Duchenne Muscular Dystrophy. AVI’s contract with the foundation is now worth a total of $5 million to develop AVI-5038, with a goal of taking the drug into … Continue reading “AVI Gets $3M For Muscular Dystrophy”
Cell Therapeutics Shares Boom, Vulcan’s Breast Cancer Bombshell, Microsoft Buys Rosetta Assets, & More Seattle-Area Life Sciences News
Most of Seattle’s biotech news this week came out of Orlando, FL, where local companies vied for the attention of 30,000 cancer specialists at the American Society of Clinical Oncology annual meeting. The best clinical trial data I saw didn’t actually come from a Seattle-based company—but it had a strong local tie to Paul Allen’s … Continue reading “Cell Therapeutics Shares Boom, Vulcan’s Breast Cancer Bombshell, Microsoft Buys Rosetta Assets, & More Seattle-Area Life Sciences News”
Contentious Biogen Idec Meeting Delayed; Icahn Nominee Objects, Saying “This is Not North Korea”
Shareholders of Cambridge, MA-based Biogen Idec (NASDAQ: [[ticker:BIIB]]) will have to wait a while to hear the outcome of the hotly contested board election. The company’s board called a recess during the annual meeting before results were announced on whether billionaire investor Carl Icahn was able to gain any seats on the company’s 13-member board. … Continue reading “Contentious Biogen Idec Meeting Delayed; Icahn Nominee Objects, Saying “This is Not North Korea””
Novocell Snaps Up Second Stem Cell Patent, New CEO Pursues “Next Big Field” of Biotech
San Diego-based Novocell has nailed down a second important patent on a valuable type of cell derived from human embryonic stem cells, which could end up forcing a lot of researchers to license technology from the company on Torrey Pines Mesa. The company is announcing today it has secured a U.S. patent that protects its … Continue reading “Novocell Snaps Up Second Stem Cell Patent, New CEO Pursues “Next Big Field” of Biotech”
Biogen Idec Showdown with Carl Icahn Culminates in Shareholder Vote Today
Shareholders of Cambridge, MA-based Biogen Idec (NASDAQ: [[ticker:BIIB]]) will have their say today on whether or not they want billionaire investor Carl Icahn’s nominees to shake things up in the boardroom. The votes will be tallied at the company’s annual meeting being held at 9 am Eastern time today at the American Academy of Arts … Continue reading “Biogen Idec Showdown with Carl Icahn Culminates in Shareholder Vote Today”
CTI Looks to Erase $119M Debt
Cell Therapeutics (NASDAQ: [[ticker:CTIC]]), the Seattle-based developer of cancer drugs, said today it is modifying an auction process in hopes to eliminate all of its $118.9 million in debt. The company announced plans to unload $89.2 million in debt last month through an auction process. But evidently, it hopes to capitalize on rising demand for … Continue reading “CTI Looks to Erase $119M Debt”
EnerG2 Snaps Up $2.5M
EnerG2, a Seattle-based company developing ultracapacitors to make it more efficient to store energy, has secured an additional $2.5 million in equity and options, according to a regulatory filing. The company raised an initial $8.5 million in October from Kirkland, WA-based OVP Venture Partners, and Palo Alto, CA-based Firelake Capital Management, a scoop first reported … Continue reading “EnerG2 Snaps Up $2.5M”
Amylin Chairman, Lead Director Ousted as Dissidents Gain Two Board Seats
The shareholders of San Diego-based Amylin Pharmaceuticals (NASDAQ: [[ticker:AMLN]]) have spoken, and they’ve ousted the company’s chairman of the board and the lead independent director. Amylin chairman Joseph Cook and lead independent director James Wilson lost their bid for re-election, the company said today, after votes were tallied from the shareholder meeting of May 27. … Continue reading “Amylin Chairman, Lead Director Ousted as Dissidents Gain Two Board Seats”
To Build or Buy? Microsoft Amps Up Life Sciences Strategy By Buying Rosetta Biosoftware
Microsoft has been angling toward the life sciences software market for years, and yesterday it made a significant play in the sector by scooping up an industry pioneer just a few miles away. The Redmond, WA-based software company said yesterday it is acquiring the assets of Rosetta Biosoftware, a Seattle-based division of Merck that has … Continue reading “To Build or Buy? Microsoft Amps Up Life Sciences Strategy By Buying Rosetta Biosoftware”
Cell Therapeutics Lymphoma Drug Boosts Remissions, Shares Boom
[Updated with share price, 4:30 pm ET] Cell Therapeutics is betting the farm on an experimental drug for non-Hodgkin’s lymphoma, and today it showed cancer doctors some evidence it hopes will convince them it’s a winner. The findings sent the company’s shares soaring by 47 percent in the last two hours of trading to close … Continue reading “Cell Therapeutics Lymphoma Drug Boosts Remissions, Shares Boom”
Microsoft, Dipping Toe Deeper into Life Sciences, Buys Rosetta Assets from Merck
Microsoft could be safely ignored on the biotech beat for years, but not anymore. The Redmond, WA-based software powerhouse, in another move to beef up its stake in the life sciences software business, said today it is acquiring the Seattle-based assets of Rosetta Biosoftware from Merck. Financial terms of the deal were not disclosed, but … Continue reading “Microsoft, Dipping Toe Deeper into Life Sciences, Buys Rosetta Assets from Merck”
Trubion Drug Kills Cancer in Blood
Trubion Pharmaceuticals (NASDAQ: [[ticker:TRBN]]), a Seattle-based developer of targeted therapies, said today that its experimental TRU-016 treatment showed encouraging results in a small trial of 26 patients with chronic lymphocytic leukemia. The drug reduced the median number of cancer cells circulating in the blood by about two-thirds, researchers said. Researchers have not yet pinpointed a … Continue reading “Trubion Drug Kills Cancer in Blood”
Alder Drug Fights Cancer Fatigue
Alder Biopharmaceuticals, the Bothell, WA-based developer of targeted antibody drugs, said today that its lead drug candidate was found to be safe and reduce severe fatigue of patients in an early-stage study of patients with advanced cancer. The trial enrolled nine patients who got ALD518, an antibody that’s designed to block an inflammatory protein called … Continue reading “Alder Drug Fights Cancer Fatigue”
Seattle Genetics Pockets $11.5M
Seattle Genetics, the Bothell, WA-based developer of targeted antibody drugs, has raised another $11.5 million, according to a regulatory filing. The company received approval from existing shareholders sell more shares to Baker Brothers Life Sciences, an investment firm led by one of the firm’s directors, Felix Baker. The $11.5 million sale was a follow-on transaction … Continue reading “Seattle Genetics Pockets $11.5M”
ASCO Weekend Recap: OncoGenex, Seattle Genetics, Vulcan-Backed BiPar Show Off Cancer Drug Results
Lots of news from the world of cancer research came out over the weekend at the American Society of Clinical Oncology meeting in Orlando, FL. There was a lot of impressive data coming out of Northwest companies (although most of it is still quite preliminary), so here’s a quick recap to catch up. The conference, … Continue reading “ASCO Weekend Recap: OncoGenex, Seattle Genetics, Vulcan-Backed BiPar Show Off Cancer Drug Results”
Seattle Genetics “Empowered Antibody” Wipes Out Hodgkin’s Tumors in Early Study
Seattle Genetics offered some more evidence, albeit quite preliminary, that suggests it may have a powerful new drug for Hodgkin’s disease and related lymphomas. The Bothell, WA-based biotech company (NASDAQ: [[ticker:SGEN]]) said today about half of patients who failed on multiple previous treatments had their tumors shrink after taking its experimental SGN-35 drug, and more … Continue reading “Seattle Genetics “Empowered Antibody” Wipes Out Hodgkin’s Tumors in Early Study”
ASCO Weekend Highlights: ImmunoGen, Antigenics, Aveo Show Off Cancer Drug Findings
There were hundreds of companies vying for the attention of 30,000 cancer specialists the past couple days at the American Society of Clinical Oncology meeting in Orlando, FL. Here’s a quick recap of highlights from New England companies that have presented data so far. The conference continues today and tomorrow. —ImmunoGen: The Waltham, MA-based biotech … Continue reading “ASCO Weekend Highlights: ImmunoGen, Antigenics, Aveo Show Off Cancer Drug Findings”
Infinity Sees Comeback Potential for Cancer Drug that Failed
Infinity Pharmaceuticals isn’t ready to pull the plug on its lead cancer drug candidate after it failed last month in a clinical trial. The Cambridge, MA-based biotech company (NASDAQ: [[ticker:INFI]]) says it sees a way forward with the drug, IPI-504, as long as it switches to a lower dose, and by giving it to patients … Continue reading “Infinity Sees Comeback Potential for Cancer Drug that Failed”
Antigenics, Digging Through Old Data, Sees Survival Edge for Cancer Vaccine
Some biostatisticians may scoff, but Antigenics is not giving up on its treatment to stimulate the immune system to fight cancer. The Lexington, MA-based biotech company (NASDAQ: [[ticker:AGEN]]) has found that nine years after its most important clinical trial began, its experimental drug appears to be helping certain kidney cancer patients live longer. The data … Continue reading “Antigenics, Digging Through Old Data, Sees Survival Edge for Cancer Vaccine”
ZymoGenetics Kidney Cancer Drug Shrinks, Stabilizes Tumors in Sickest Patients
ZymoGenetics (NASDAQ: [[ticker:ZGEN]]) is getting out of the business of developing cancer drugs, but it may have at least one potential valuable asset to put up for sale. The Seattle-based biotech company said its IL-21 drug was able to shrink and stabilize tumors in a small clinical trial of some of the sickest patients with … Continue reading “ZymoGenetics Kidney Cancer Drug Shrinks, Stabilizes Tumors in Sickest Patients”
Breast Cancer Bombshell: Vulcan-Backed BiPar Wows Scientists, Helps Women Live Longer
[[Updated with scientist comment, 1:20 pm ET]] Billionaire Paul Allen made windfall profits from his investment in BiPar Sciences, and today we can really see why. The Brisbane, CA-based biotech company founded by Allen’s Vulcan investment firm said today that its drug candidate for women with an aggressive form of breast cancer was able to … Continue reading “Breast Cancer Bombshell: Vulcan-Backed BiPar Wows Scientists, Helps Women Live Longer”
OncoGenex Drug Helps Prostate Cancer Patients Live Longer in Small Study
OncoGenex Pharmaceuticals’ stock has busted out from obscurity in the past couple of weeks, and today it’s showing what the fuss is all about. The Bothell, WA-based biotech company (NASDAQ: [[ticker:OGXI]]) is reporting that its experimental prostate cancer drug was able to help men live longer in a small clinical trial, a finding which suggests … Continue reading “OncoGenex Drug Helps Prostate Cancer Patients Live Longer in Small Study”
Calistoga Picks Up Buzz at ASCO, Thanks to Momentum from Rival
Last Wednesday night, the top dealmaker at Seattle-based Calistoga Pharmaceuticals got a tip that one of his rivals was on the verge of striking a huge deal. Cliff Stocks, the chief business officer, told CEO Carol Gallagher he was hopeful the rumor was true—that some Big Pharma company would pay a fortune for an experimental … Continue reading “Calistoga Picks Up Buzz at ASCO, Thanks to Momentum from Rival”
Aveo Kidney Cancer Drug, Challenging Pfizer and Bayer, Passes Important Test
Cambridge, MA-based Aveo Pharmaceuticals is releasing important data today that suggests it may by on its way to developing a better way to cut off blood supply to tumors. An experimental drug from Aveo was able to at least partially shrink tumors for one-fourth of patients, and keep the cancer from spreading for a median … Continue reading “Aveo Kidney Cancer Drug, Challenging Pfizer and Bayer, Passes Important Test”
Can the Feds Get Into the Biotech VC Business? Bionager Wants to Make It Happen
Washington state gets more than $1 billion every year from the federal government to support biomedical research, which makes a lot of entrepreneurs wonder why there aren’t more startups being spun out each year. Now a couple of well-known Northwest life sciences entrepreneurs, Tom Ranken and Bob Wilcox, want to take a little more money … Continue reading “Can the Feds Get Into the Biotech VC Business? Bionager Wants to Make It Happen”
Vulcan’s Biotech Windfall, Tekmira Tackles RNAi Delivery, The $1,000 Genome Debate, & More Seattle-Area Life Sciences News
The usual suspects in Seattle biotech were quiet this week, but we reported on an intriguing cancer drug developer with Paul Allen’s fingerprints all over it, as well as some compelling life sciences companies from British Columbia. —Vulcan Capital, the investment vehicle that controls billionaire Paul Allen‘s fortune, quietly dialed back its biotech investing a … Continue reading “Vulcan’s Biotech Windfall, Tekmira Tackles RNAi Delivery, The $1,000 Genome Debate, & More Seattle-Area Life Sciences News”
CTI Loses $4.3M Arbitration
Cell Therapeutics (NASDAQ: [[ticker:CTIC]]), the Seattle-based developer of cancer drugs, said today in a regulatory filing that it lost an arbitration dispute with Irvine, CA-based Spectrum Pharmaceuticals worth $4.3 million. In February, CTI sold its remaining stake in the lymphoma drug ibritumomab tiuxetan (Zevalin) to Spectrum for $16.5 million. In April, Spectrum refused to pay … Continue reading “CTI Loses $4.3M Arbitration”